 SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 GLOBE NEWSWIRE -- Calithera Biosciences, Inc. Nasdaq: CALA, a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, has been awarded up to 2.4M from the Cystic Fibrosis Foundation. The award will support clinical development of CB-280, Calitheras investigational first-in-class arginase inhibitor, which promotes higher tissue levels of nitric oxide NO to reduce the risk of infections in people with cystic fibrosis CF. 